Herpes Viruses Fear mRNA Vaccine Candidate
About 4 billion people eagerly await a vaccine to prevent and/or treat herpes virus infections, a global Sexually Transmitted Disease (STD).
According to the World Health Organization, an estimated 3.7 billion people have herpes simplex virus type 1 (HSV-1) infection, the leading cause of oral herpes.
Additionally, an estimated 491 million people have herpes simplex virus type 2 (HSV-2) infection, the main cause of genital herpes.
Recently, a worldwide leader in mRNA technologies launched a phase 1/2 clinical trial to address this massive market.
Moderna Inc.'s mRNA-1608 is an HSV-2 therapeutic vaccine candidate conducting a study (mRNA-1608-P101) with 300 healthy adults with recurrent HSV-2 Genital Herpes.
This randomized, observer-blind, controlled, dose-ranging study launched in the United States on September 6, 2023, and is forecasted to be completed on June 4, 2025.
With mRNA-1608, Moderna aims to induce a strong antibody response with neutralizing and effector functionality combined with cell-mediated immunity.
On February 18, 2022, Moderna stated that it expects an HSV-2 vaccine could provide cross-protection against HSV-1.
As of September 15, 2023, there is no herpes vaccine candidate approved by the U.S. Food and Drug Administration.